Company Overview and News
PHILIPPINE Airlines (PAL) is set to add domestic routes from its hub at the Clark International Airport this year, starting with the launch of Clark-Siargao flights on Saturday.
PHILIPPINE Airlines (PAL) could expect the delivery of its A350-900 aircraft soon as Airbus reported it has successfully flown the new airplane from the assembly line in Toulouse, France, gearing it up for the final phase of production.
Philippine Airlines (PAL) could expect the delivery of its A350-900 aircraft soon as Airbus reported it has successfully flown the new airplane from the assembly line in Toulouse, France, gearing it up for the final phase of production.
Flag carrier Philippine Airlines (PAL) said ticket prices were likely to increase given the rising cost of oil coupled with the weakening peso.
2018-04-15 bworldonline - 1
PHILIPPINE Airlines (PAL) is planning to mount nonstop flights from Manila to New Delhi and Mumbai in India and to Sapporo in Japan by the fourth quarter, as the flag carrier expects 15 new aircraft to be delivered this year.
The operator of flag carrier Philippine Airlines swung to a loss in 2017 as expenses soar. PAL Holdings Inc., in a stock exchange filing yesterday, said losses last year amounted to P7.33 billion compared to a profit of P4.13 billion in 2016.
PAL HOLDINGS, Inc. swung to a P7.3 billion net loss attributable to parent in 2017 from a P4.13 billion profit in the year prior, as higher fuel prices and ballooning aircraft and passenger expenses weighed on the bottom line.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to PSE:PAL / PAL Holdings, Inc. on message board site Silicon Investor.